SIRT1 and other NAD-dependent deacetylases have been implicated in control of cellular responses to stress and in tumorigenesis through deacetylation of important regulatory proteins, including p53 and the BCL6 oncoprotein. Hereby, we describe the identification of a compound we named cambinol that inhibits NAD-dependent deacetylase activity of human SIRT1 and SIRT2. Consistent with the role of SIRT1 in promoting cell survival during stress, inhibition of SIRT1 activity with cambinol during genotoxic stress leads to hyperacetylation of key stress response proteins and promotes cell cycle arrest. Treatment of BCL6-expressing Burkitt lymphoma cells with cambinol as a single agent induced apoptosis, which was accompanied by hyperacetylation of BCL6 and p53. Because acetylation inactivates BCL6 and has the opposite effect on the function of p53 and other checkpoint pathways, the antitumor activity of cambinol in Burkitt lymphoma cells may be accomplished through a combined effect of BCL6 inactivation and checkpoint activation. Cambinol was well tolerated in mice and inhibited growth of Burkitt lymphoma xenografts. Inhibitors of NADdependent deacetylases may constitute novel anticancer agents. (Cancer Res 2006; 66(8): 4368-77)
We developed a 'computational second-site suppressor' strategy to redesign specificity at a protein-protein interface and applied it to create new specifically interacting DNase-inhibitor protein pairs. We demonstrate that the designed switch in specificity holds in in vitro binding and functional assays. We also show that the designed interfaces are specific in the natural functional context in living cells, and present the first high-resolution X-ray crystallographic analysis of a computer-redesigned functional protein-protein interface with altered specificity. The approach should be applicable to the design of interacting protein pairs with novel specificities for delineating and re-engineering protein interaction networks in living cells.
Sirtuins
are a family of NAD+-dependent protein deacetylases
that play critical roles in epigenetic regulation, stress responses,
and cellular aging in eukaryotic cells. In an effort to identify small
molecule inhibitors of sirtuins for potential use as chemotherapeutics
as well as tools to modulate sirtuin activity, we previously identified
a nonselective sirtuin inhibitor called cambinol (IC50 ≈
50 μM for SIRT1 and SIRT2) with in vitro and in vivo antilymphoma activity. In the current study, we
used saturation transfer difference (STD) NMR experiments with recombinant
SIRT1 and 20 to map parts of the inhibitor that interacted
with the protein. Our ongoing efforts to optimize cambinol analogues
for potency and selectivity have resulted in the identification of
isoform selective analogues: 17 with >7.8-fold selectivity
for SIRT1, 24 with >15.4-fold selectivity for SIRT2,
and 8 with 6.8- and 5.3-fold selectivity for SIRT3 versus
SIRT1 and SIRT2, respectively. In vitro cytotoxicity studies with
these compounds as well as EX527, a potent and selective SIRT1 inhibitor,
suggest that antilymphoma activity of this compound class may be predominantly
due to SIRT2 inhibition.
Manipulating gene expression in zebrafish is critical for exploiting the full potential of this vertebrate model organism. Morpholino oligos are the most commonly employed antisense technology for knocking down gene expression. However, morpholinos suffer from a lack of control over the timing and location of knockdown. In this report, we describe a novel lightactivatable knockdown reagent called PhotoMorph™. PhotoMorphs can be generated from existing morpholinos by hybridization with a complementary caging strand containing a photocleavable linkage. The caging strand neutralizes the morpholino activity until irradiation of the PhotoMorph with UV light releases the morpholino. We generated PhotoMorphs to target genes encoding enhanced green fluorescent protein (EGFP), No tail, and E-cadherin to illustrate the utility of this approach. Temporal control of gene expression with PhotoMorphs permitted us to circumvent the early lethal phenotype of E-cadherin knockdown. A splice-blocking PhotoMorph directed to the rheb gene showed light-dependent gene knockdown up to 72 hpf. PhotoMorphs thus offer a new class of laboratory reagents suitable for the spatiotemporal control of gene expression in the zebrafish.
The
G protein-coupled chemokine receptors CXCR1 and CXCR2 play
key roles in inflammatory diseases and carcinogenesis. In inflammation,
they activate and recruit polymorphonuclear cells (PMNs) through binding
of the chemokines CXCL1 (CXCR1) and CXCL8 (CXCR1 and CXCR2). Structure–activity
studies that examined the effect of a novel series of S-substituted
6-mercapto-N-phenyl-nicotinamides on CXCL1-stimulated
Ca2+ flux in whole human PMNs led to the discovery of 2-[5-(4-fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic
acid (SX-517), a potent noncompetitive boronic acid CXCR1/2 antagonist.
SX-517 inhibited CXCL1-induced Ca2+ flux (IC50 = 38 nM) in human PMNs but had no effect on the Ca2+ flux
induced by C5a, fMLF, or PAF. In recombinant HEK293 cells that stably
expressed CXCR2, SX-517 antagonized CXCL8-induced [35S]GTPγS
binding (IC50 = 60 nM) and ERK1/2 phosphorylation. Inhibition
was noncompetitive, with SX-517 unable to compete the binding of [125I]-CXCL8 to CXCR2 membranes. SX-517 (0.2 mg/kg iv) significantly
inhibited inflammation in an in vivo murine model. SX-517 is the first
reported boronic acid chemokine antagonist and represents a novel
pharmacophore for CXCR1/2 antagonism.
N-[4-[[(2,4-diamino-6-pterdinyl)
methyl]amino]benzoyl]-L/D-glutamic acid (L/D-AMT)is an investigational drug in phase 1 clinical development that consists of the L-and D-enantiomers of aminopterin (AMT). L/D-AMT is obtained from a novel process for making the L-enantiomer (L-AMT), a potent oral antiinflammatory agent. The purpose of these studies was to characterize oral uptake and safety in the dog and human of each enantiomer alone and in combination and provide in vitro evidence for a mechanism of intestinal absorption. This is the first report of L /D-AMT in humans. In dogs (n ϭ 40) orally dosed with L-AMT or D-AMT absorption was stereoselective for the L-enantiomer (6-to 12-fold larger peak plasma concentration after oral administration and area under the plasma concentration-time curve at 0 -4 h; p Ͻ 0.001). D-AMT was not toxic at the maximal dose tested (82.5 mg/kg), which was 100-fold larger than the maximal nonlethal L-AMT dose (0.8 mg/kg). Dogs (n ϭ 10) and humans with psoriasis (n ϭ 21) orally administered L-AMT and L /D-AMT at the same L-enantiomer dose resulted in stereoselective absorption (absent D-enantiomer in plasma), bioequivalent L-enantiomer pharmacokinetics, and equivalent safety. Thus, the D-enantiomer in L/D-AMT did not perturb L-enantiomer absorption or alter the safety of L-AMT. In vitro uptake by the human proton-coupled folate transporter (PCFT) demonstrated minimal transport of D-AMT compared with L-AMT, mirroring the in vivo findings. Enantiomer selectivity by PCFT was attributable almost entirely to decreased binding affinity rather than changes in transport rate. Collectively, our results demonstrate a strong in vitro-in vivo correlation implicating stereoselective transport by PCFT as the mechanism underlying stereoselective absorption observed in vivo.
The chemokine receptors CXCR1 and CXCR2 are important pharmaceutical targets due
to their key roles in inflammatory diseases and cancer progression. We have previously
identified 2-[5-(4-Fluoro-phenylcarbamoyl)-pyridin-2-ylsulfanylmethyl]-phenylboronic acid
(SX-517) and 6-(2-boronic
acid-5-trifluoromethoxy-benzylsulfanyl)-N-(4-fluoro-phenyl)-nicotinamide
(SX-576) as potent non-competitive boronic acid-containing CXCR1/2 antagonists. Herein we
report the synthesis and evaluation of aminopyridine and aminopyrimidine analogues of
SX-517 and SX-576, identifying (2-{(Benzyl)[(5-boronic
acid-2-pyridyl)methyl]amino}-5-pyrimidinyl)(4-fluorophenylamino)formaldehyde as a potent
chemokine antagonist with improved aqueous solubility and oral bioavailability.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.